Loading, please wait...
Date: Jun 28, 2023 07:00 PM - 08:00 PM
Location: UIW Feik School of Pharmacy, 703 E. Hildebrand, San Antonio, TX, 78212
CE Hours
1.00
CE Units
0.100
Registration closes on Aug 09, 2023 11:55 PM
Activity Type
- Application
Target Audience(s)
- Pharmacists
Accreditation(s)
|
The University of the Incarnate Word Feik School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Joint Provider(s)
Bexar County Pharmacy Association (BCPA) and Central Texas Society of Health-System Pharmacists (CTSHP)
Requirements for CE Credit
- The participant will only receive credit for programs after receiving a 70% on a post-test and an evaluation form is completed and submitted.
- The entire session must be attended to receive credit. No partial credit will be given.
- Certificates will not be mailed. Contact hours will be uploaded to NABP's CPE Monitor after successful completion of post-test and program evaluation.
- To receive credit, participant profiles must contain a valid NABP e-profile ID number and month/date of birth.
- All requirements to receive credit must be completed within six weeks of participation in the CPE program. Failure to complete requirements within the six-week window will result in no credit awarded to the participant.
|
Please choose a Fee Type from the Drop Down Menu Below:
I am a
|
Registration closes on Aug 09, 2023
at 11:55 PM
Registration closes on Aug 09, 2023
at 11:55 PM
Registration Closed
Registration Closed
Upon the completion of this activity, pharmacist will be able to:
1. Analyze the relationship between receptor binding profiles and the adverse effects of antipsychotics.
2. Identify the prevalence, risk factors, and significance of common adverse effects associated with antipsychotic
medications.
3. Evaluate potential risk for metabolic syndrome, QTc prolongation, hyperprolactinemia, and anticholinergic burdens
in patients receiving antipsychotic medications.
4. Outline the management, prevention, and clinical judgement involved for each antipsychotic related adverse effect.
5. Emphasize the origins and clinical significance of the Black Box Warning (BBW) for increased mortality associated
with antipsychotic use in elderly patients with dementia-related psychosis.
6. Describe the symptomology and onset of Extrapyramidal Symptoms (EPS) and Tardive Dyskinesia (TD) associated
with antipsychotic use and outline their prevention and treatment.
2. Identify the prevalence, risk factors, and significance of common adverse effects associated with antipsychotic
medications.
3. Evaluate potential risk for metabolic syndrome, QTc prolongation, hyperprolactinemia, and anticholinergic burdens
in patients receiving antipsychotic medications.
4. Outline the management, prevention, and clinical judgement involved for each antipsychotic related adverse effect.
5. Emphasize the origins and clinical significance of the Black Box Warning (BBW) for increased mortality associated
with antipsychotic use in elderly patients with dementia-related psychosis.
6. Describe the symptomology and onset of Extrapyramidal Symptoms (EPS) and Tardive Dyskinesia (TD) associated
with antipsychotic use and outline their prevention and treatment.
Speaker(s)/Author(s)
|
Joshua Knebel, PharmD
|
Activity Number
0445-9999-23-013-L01-P
Date:
06/28/23
Time:
07:00 PM - 07:45 PM
CE Hours
1.00
Location
FSOP 513
Registration Closed